FBRX

Forte BiosciencesF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$36.00

+98.1% vs current

Most likely

Base case

45%

Probability

Target price

$21.00

+15.5% vs current

B-

Bear case

30%

Probability

Target price

$11.00

-39.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-16

AI commentary

This was a scheduled T+3 earnings follow-up, but the company actually reported on May 11, 2026 and filed the related 8-K on May 14, 2026. Market reaction looked initially positive but not durable: shares closed at $26.00 on May 11, 2026, fell to $24.29 on May 12, and closed at $24.66 on May 13, versus $24.02 on May 8. That pattern fits a cautious read that the earnings release and Fast Track news supported the story, but did not fundamentally change the market's wait-for-data posture. Headline flow is active, yet coverage remains thin and delayed post-print analyst revisions were not clearly available by May 16, 2026.

RankAlpha Sentiment Codex - 2026-05-16

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-11eventQ1 update confirmed cash runway extension after April financingHigh impact

Forte reported Q1 2026 cash and cash equivalents of $58.2 million and said existing cash plus net proceeds from the April 8, 2026 offering should fund operations for at least twelve months from the May 11, 2026 Form 10-Q filing date; the same earnings update also reiterated active FB102 development across celiac disease, vitiligo, and alopecia areata. [#10-Q-2026-05-11] [#8-K-2026-05-14]

2026-06-30catalystFB102 vitiligo Phase 1b topline was guided to arrive shortlyHigh impact

Management said in the May 11, 2026 earnings release that the FB102 Phase 1b vitiligo study is expected to have topline results shortly, making it the nearest clean clinical catalyst after the post-earnings update. [#8-K-2026-05-14] [#10-Q-2026-05-11]

2026-09-30catalystFB102 celiac Phase 2 and alopecia areata readouts remain the core 2026 value driversHigh impact

Forte reiterated that Phase 2 celiac disease topline results are expected in 2026 and that alopecia areata Phase 1b data are also expected in 2026; the May update also highlighted FDA Fast Track designation for FB102 in celiac disease, which helps regulatory visibility but does not remove binary data risk. [#8-K-2026-05-14] [#10-Q-2026-05-11]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-16 • Updated nightlySource: Internal modelMethodology